Kalaris Therapeutics announced positive Phase 1a data for TH103 in treating neovascular age-related macular degeneration (nAMD).
TH103 showed significant improvements in visual acuity and anatomic changes in treatment-naïve patients.
The data suggests extended treatment durability and enhanced VEGF inhibition with TH103.
Enhanced Potency and Intraocular Retention
TH103 demonstrated improved binding to heparan sulfate proteoglycans (HSPG) and slower systemic clearance compared to aflibercept.
Rapid Clinical Activity
Patients showed rapid and robust improvements in visual acuity and central subfield thickness after a single injection of TH103.
Well Tolerated Treatment
TH103 was generally well tolerated, with no dose-limiting toxicities or serious adverse events observed.
- The initial Phase 1a data indicate strong clinical activity and support TH103's molecular design.
- The pharmacokinetic profile of TH103 shows significantly lower plasma levels compared to leading anti-VEGF agents, suggesting enhanced intraocular retention.
The promising results from the Phase 1a trial of TH103 highlight its potential as a breakthrough treatment for neovascular AMD. Kalaris Therapeutics plans to continue exploring TH103's efficacy and safety in further studies.